Onconova Therapeutics Inc. cheered investors by disclosing the submission of an investigational new drug (IND) application to the FDA to test the intravenous (I.V.) formulation of rigosertib in a pivotal phase III study in higher-risk myelodysplastic syndromes (HR-MDS) after the failure of a hypomethylating agent (HMA).